"Flow Cytometry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
| Descriptor ID |
D005434
|
| MeSH Number(s) |
E01.370.225.500.363.342 E01.370.225.500.386.350 E05.196.712.516.600.240.350 E05.200.500.363.342 E05.200.500.386.350 E05.242.363.342 E05.242.386.350
|
| Concept/Terms |
Flow Cytometry- Flow Cytometry
- Microfluorometry, Flow
- Flow Microfluorometries
- Flow Microfluorometry
- Microfluorometries, Flow
- Flow Microfluorimetry
- Microfluorimetry, Flow
- Cytofluorometry, Flow
- Cytofluorometries, Flow
- Flow Cytofluorometries
- Flow Cytofluorometry
- Cytometry, Flow
- Cytometries, Flow
- Flow Cytometries
Fluorescence-Activated Cell Sorting- Fluorescence-Activated Cell Sorting
- Cell Sorting, Fluorescence-Activated
- Cell Sortings, Fluorescence-Activated
- Fluorescence Activated Cell Sorting
- Fluorescence-Activated Cell Sortings
- Sorting, Fluorescence-Activated Cell
- Sortings, Fluorescence-Activated Cell
|
Below are MeSH descriptors whose meaning is more general than "Flow Cytometry".
Below are MeSH descriptors whose meaning is more specific than "Flow Cytometry".
This graph shows the total number of publications written about "Flow Cytometry" by people in this website by year, and whether "Flow Cytometry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 2 | 4 | 6 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 2 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Flow Cytometry" by people in Profiles.
-
Combinatorial multimer staining and spectral flow cytometry facilitate quantification and characterization of polysaccharide-specific B cell immunity. Commun Biol. 2023 10 28; 6(1):1095.
-
Inducing apoptosis using chemical treatment and acidic pH, and detecting it using the Annexin V flow cytometric assay. PLoS One. 2022; 17(6):e0270599.
-
?d T cell frequencies are altered in HIV positive pregnant South African women and are associated with preterm birth. PLoS One. 2020; 15(6):e0235162.
-
Measuring the ability of HIV-specific antibodies to mediate trogocytosis. J Immunol Methods. 2018 12; 463:71-83.
-
Absence of Acanthocytosis in Huntington's Disease-like 2: A Prospective Comparison with Huntington's Disease. Tremor Other Hyperkinet Mov (N Y). 2017; 7:512.
-
Choosing a new CD4 technology: Can statistical method comparison tools influence the decision? Cytometry B Clin Cytom. 2017 11; 92(6):465-475.
-
LRP/LR Antibody Mediated Rescuing of Amyloid-ß-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease. J Alzheimers Dis. 2016; 49(3):645-57.
-
Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer. J Immunol Methods. 2015 Nov; 426:1-13.
-
Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia. 2015 Jul; 29(7):1514-23.
-
The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro. Mediators Inflamm. 2014; 2014:105420.